ZUG, Switzerland, January 21 /PRNewswire/ -- Swiss Hawk AG is proud to announce that overall the Company's seven investment portfolio participations performed very well during 2007 and are on course for significant growth in value during 2008.

The company expects to start a disposal from its holdings in quoted companies from March 2008 and onwards.

It is expected that all unquoted investment holdings will be quoted on a recognised stock exchange or will be disposed through trade sales during the coming three months. At the time of listing of the unquoted companies a disposal plan will be agreed on.

It is the Company's policy to make investments only when a short term Exit plan is in place, with Exit timeframe being approximately 12 months.

COPENHAGEN, January 21 /PRNewswire/ --

- Summary: Genmab has Achieved two Development Milestones in its Ofatumumab Collaboration with GlaxoSmithKline

Genmab A/S (OMX: GEN) announced today it has reached the second and third development milestones for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration with GlaxoSmithKline (GSK).

The second milestone payment of the collaboration of DKK 87.2 million was triggered by treatment of the first patient in the Phase II study of ofatumumab in Diffuse Large B-Cell Lymphoma (DLBCL), which occurred in 2007. The third milestone payment of DKK 87.2 million was triggered by the first patient receiving treatment in the Phase III rheumatoid arthritis (RA) program, which occurred in 2008.

LOS ANGELES, January 21 /PRNewswire/ --

- Following FDA Approval, Company Announces US$7,800 Wholesale Price for Lifesaving Drug

INNER MONGOLIA, China, January 21 /PRNewswire/ --

- With Photo

- Collaborative journalism project covers front lines of global water crisis

Furious dust and sandstorms from Inner Mongolia cripple airports, darken skies, and choke millions of people across East Asia every spring. According to "Reign of Sand," the new multimedia report from Circle of Blue (http://www.circleofblue.org), the storms are growing in intensity and frequency, and the primary causes are deepening drought in northern China and the mismanagement of the largest grasslands on earth.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080121/DC11917 )

ANDOVER, England, January 21 /PRNewswire/ -- Ever had your conscience nagging at you? "Go to the dentist?", "Get your blood pressure checked?" Well, "Hey, jus' say!"

Introducing "the Sleeve", the voice of your health conscience and the new face of HSA - the UK's favourite Healthplan provider. This reassuring and recognisable character will appear across all of HSA's marketing material and advertising from 20 January 2008, including national television advertising.

EDINBURGH, January 21 /PRNewswire/ --

- Edinburgh-Based Aircraft Medical Ready to Fight GBP37m Court Action

Aircraft Medical ("Aircraft"), the UK medical devices company announces that it will rigorously defend a patent infringement case commenced in the Court of Session, Edinburgh by a competitor, Verathon (based in Seattle, USA). Verathon is claiming GBP37m in damages.

Verathon has claimed that the McGrath(R) Series 5 Video Laryngoscope, manufactured by Aircraft Medical in Scotland, infringes its European Patent 1307131, and by some undisclosed means has calculated damages in lost sales of GBP37m.